Sam Brusco, Associate Editor09.02.22
Dexcom has promoted chief technology officer (CTO) Jake Leach to the role of chief operating officer (COO).
An 18-year Dexcom veteran, Leach has served as CTO since 2018. He began his tenure in 2004 to lead development of sensor electronics for Dexcom’s first commercial continuous glucose monitoring (CGM) system. Since then, he’s led teams in charge of development of multiple Dexcom CGM generations, up to and including Dexcom G6.
“For nearly two decades, Jake has helped lead technology development at Dexcom, ensuring our organization is on the forefront of innovation in continuous glucose monitoring and data connectivity,” Kevin Sayer, chairman, president and CEO of Dexcom told the press. “In this new role, Jake will expand upon his proven leadership and industry expertise to ensure that Dexcom remains at the forefront of sensing technology and well-positioned to bring Dexcom CGM to the millions of additional people who stand to benefit from it.”
As COO, Leach will head global operations, research and development, quality management, and regulatory efforts.
The Dexcom G7 CGM earned CE mark approval in March, and is currently under U.S. Food and Drug Administration (FDA) review.
An 18-year Dexcom veteran, Leach has served as CTO since 2018. He began his tenure in 2004 to lead development of sensor electronics for Dexcom’s first commercial continuous glucose monitoring (CGM) system. Since then, he’s led teams in charge of development of multiple Dexcom CGM generations, up to and including Dexcom G6.
“For nearly two decades, Jake has helped lead technology development at Dexcom, ensuring our organization is on the forefront of innovation in continuous glucose monitoring and data connectivity,” Kevin Sayer, chairman, president and CEO of Dexcom told the press. “In this new role, Jake will expand upon his proven leadership and industry expertise to ensure that Dexcom remains at the forefront of sensing technology and well-positioned to bring Dexcom CGM to the millions of additional people who stand to benefit from it.”
As COO, Leach will head global operations, research and development, quality management, and regulatory efforts.
The Dexcom G7 CGM earned CE mark approval in March, and is currently under U.S. Food and Drug Administration (FDA) review.